Ipsat Therapies Oy

Studies from University of Calgary reveal new findings on drug resistance.
Biotech Week; 10/7/2009; 1002 words; ...study from Calgary, Canada, "Ipsat Therapies Oy is developing IPSAT (intestinal protection system...a class A beta-lactamase therapy that targets the penicillins...In preclinical studies, IPSAT P1A, when administered with...

Ipsat Therapies Oy-Company Report.
M2 Presswire; 2/9/2009; 493 words; ...February 2009-www.companiesandmarkets.com: Ipsat Therapies Oy-Company Report(C)1994-2009 M2 COMMUNICATIONS...www.companiesandmarkets.com adds new report: Ipsat Therapies Oy-Company Report Private Company Reports provide...

Finnish Inventors Develop Non-Sporulating Bacillus Subtilis
US Fed News Service, Including US State News; 1/17/2008; 405 words; ...disclosed." The inventors were issued U.S. Patent No. 7,319,030 on Jan. 15. The patent has been assigned to Ipsat Therapies Oy, Espoo. The original application was filed on Nov. 5, 2002, and is available at: http://patft.uspto...

Covalent Group, Inc. Announces Results of Shareholder Vote.
Business Wire; 10/20/2006; 2085 words; ...Lindevall is also Co-Founder of Ipsat Therapies Oy/Ltd., a Finnish biotechnology company developing its proprietary IPSAT[TM] ("Intestinal Protection...with Lakiasiaintoimisto Lakituki Oy, a Finnish based law firm, since...

Technology Vision Group LLC: Biotechnology Leaders Prepare to Converge on Vancouver for Premier Global Partnering Opportunity.
Business Wire; 12/9/2003; 1266 words; ...Pharmaceuticals, Ingenium Pharmaceuticals AG, Inimex Pharmaceuticals, Inc., International Wex Technologies Inc., Ipsat Therapies Oy, Isotechnika Inc., JERINI, MedPharm Ltd., MorphoSys AG, Morphotek Inc., NOBEX, Novozymes A/S, PanaGin...